Advagene Biopharma Co., Ltd.
About Advagene
Milestone
Management Team
Board of Directors
R&D PIPELINE
NEW DRUG PEPLINE
Intranasal Vaccines
Airway allergy immunotherapy
Covid-19-immunitytherapy
Other vaccine applications
News
News
Press Releases
Partnerships and Collaborators
Investors
Catalogs
公開資訊觀測站
繁體中文
English
简体中文
Contact Us
Home
News
News
AD17002-SC for the treatment of COVID-19 was approved by BPOM to perform phase II/III human clinical trials in Indonesia.
AD17002-SC for the treatment of COVID-19 was approved by BPOM to perform phase II/III human clinical trials in Indonesia.
2022-07-24
Back
繁體中文
English
简体中文